Related Experiment Videos
Key ligand interface residues in tissue factor contribute independently to factor VIIa binding
J R Schullek1, W Ruf, T S Edgington
1Department of Immunology, Scripps Research Institute, La Jolla, California 92037.
The Journal of Biological Chemistry
|July 29, 1994
Summary
Key residues on tissue factor (TF) were identified for binding coagulation factor VIIa (FVIIa). Alanine mutagenesis revealed Ile22 as an independent contact site, crucial for TF-FVIIa interaction and binding energy.
Area of Science:
- Biochemistry
- Molecular Biology
- Protein-protein interactions
Background:
- Tissue factor (TF) is a cell surface receptor crucial for initiating the coagulation cascade.
- Coagulation factor VIIa (FVIIa) is a serine protease that binds TF to form an active complex.
- Understanding the molecular basis of TF-FVIIa binding is essential for developing anticoagulants.
Purpose of the Study:
- To identify specific amino acid residues in tissue factor essential for binding coagulation factor VIIa.
- To determine the contribution of these residues to the binding affinity and free energy.
- To assess the independence of these contact sites within the TF-FVIIa complex.
Main Methods:
- Scanning alanine mutagenesis was performed on tissue factor, targeting specific residues.
- Functional assays were used to characterize ligand binding of the resulting mutants.
- Free energy of binding was calculated to quantify the impact of mutations.
Main Results:
- Mutagenesis identified Lys20, Ile22, Asp58, Arg135, and Phe140 as important for FVIIa binding.
- Single mutations reduced the free energy of binding by 1-2.5 kcal/mol.
- Ile22 was identified as an independent contact site, while Lys20/Asp58 and Arg135/Phe140 pairs did not contribute independently.
Conclusions:
- Specific residues in tissue factor are critical for high-affinity binding of coagulation factor VIIa.
- Ile22 plays a unique role as an independent contact site in the TF-FVIIa interaction.
- These findings provide insights into the structural basis of TF-FVIIa complex formation and potential therapeutic targets.